KALA BIO Inc (KALA) FinancialsKALAKALA BIO Inc

Evaluating the bottom line, KALA BIO Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -345.32%, provide a clear picture of how effectively KALA converts its operational activities into shareholder value.

In the context of the broader market, KALA competes directly with industry leaders such as MBIO and ERNA. With a market capitalization of $3.01M, it holds a significant position in the sector. When comparing efficiency, KALA's gross margin of N/A stands against MBIO's N/A and ERNA's N/A. Such benchmarking helps identify whether KALA BIO Inc is trading at a premium or discount relative to its financial performance.

KALA has shown poor financial performance with a net income loss of -$8,175,000 in Q4 2024 and a current ratio of 7.91 in Q1 2026, indicating potential liquidity issues despite having some current assets.